Targeting Insulin for Alzheimer's Disease: Mechanisms, Status and Potential Directions

Jung Hyun Lee, Jordan B. Jahrling, Larry Denner, Kelly Dineley

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Insulin resistance can occur when the body is unable to respond to insulin even in excess. In the brain, insulin manages glucose metabolism in regions such as the hippocampus and plays a key role in directly regulating ERK, a kinase required for the type of memory compromised in early Alzheimer's disease (AD). Human imaging studies show that brain glucose utilization declines with age and is notably impaired in subjects with early AD. Likewise, animal models of AD or insulin resistance, or both, demonstrate that dysfunctional insulin signaling and insulin resistance in the brain have reciprocity with neuroinflammation and aberrant accumulation of amyloid-β (Aβ), pathological hallmarks in AD. As such, the association between brain insulin activity and AD has led to clinical trials testing the efficacy of insulin and insulin-sensitizing drugs to intervene in AD. Based on recent inquiries to ClinicalTrials.gov, we evaluated thirty-three clinical studies related to AD and insulin. The search filtered for interventional clinical trials to test FDA-approved drugs or substances that impinge upon the insulin signaling pathway. Insulin, metformin, and thiazolidinediones were the three main interventions assessed. Overall, these strategies are expected to negate the effects of brain insulin resistance by targeting insulin signaling pathways involved in neuroinflammation, metabolic homeostasis, synaptic functional and structural integrity. The goal of this review is to provide an update on insulin and ERK signaling in relation to memory, its decline in early AD, and provide an overview of clinical trials related to insulin for early AD intervention.

Original languageEnglish (US)
Pages (from-to)S427-S453
JournalJournal of Alzheimer's Disease
Volume64
Issue numbers1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Alzheimer Disease
Insulin
Insulin Resistance
Brain
Direction compound
Clinical Trials
Glucose
Thiazolidinediones
Disease Resistance
Metformin
Amyloid
Pharmaceutical Preparations
Meta-Analysis
Hippocampus
Homeostasis
Phosphotransferases
Animal Models

Keywords

  • Alzheimer's disease
  • animal model
  • clinical trials
  • ERK
  • insulin resistance
  • learning and memory
  • metabolism
  • mitochondria
  • PPARγ

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

Targeting Insulin for Alzheimer's Disease : Mechanisms, Status and Potential Directions. / Lee, Jung Hyun; Jahrling, Jordan B.; Denner, Larry; Dineley, Kelly.

In: Journal of Alzheimer's Disease, Vol. 64, No. s1, 01.01.2018, p. S427-S453.

Research output: Contribution to journalReview article

@article{5482d25f1e674b889b8c0af0561f8614,
title = "Targeting Insulin for Alzheimer's Disease: Mechanisms, Status and Potential Directions",
abstract = "Insulin resistance can occur when the body is unable to respond to insulin even in excess. In the brain, insulin manages glucose metabolism in regions such as the hippocampus and plays a key role in directly regulating ERK, a kinase required for the type of memory compromised in early Alzheimer's disease (AD). Human imaging studies show that brain glucose utilization declines with age and is notably impaired in subjects with early AD. Likewise, animal models of AD or insulin resistance, or both, demonstrate that dysfunctional insulin signaling and insulin resistance in the brain have reciprocity with neuroinflammation and aberrant accumulation of amyloid-β (Aβ), pathological hallmarks in AD. As such, the association between brain insulin activity and AD has led to clinical trials testing the efficacy of insulin and insulin-sensitizing drugs to intervene in AD. Based on recent inquiries to ClinicalTrials.gov, we evaluated thirty-three clinical studies related to AD and insulin. The search filtered for interventional clinical trials to test FDA-approved drugs or substances that impinge upon the insulin signaling pathway. Insulin, metformin, and thiazolidinediones were the three main interventions assessed. Overall, these strategies are expected to negate the effects of brain insulin resistance by targeting insulin signaling pathways involved in neuroinflammation, metabolic homeostasis, synaptic functional and structural integrity. The goal of this review is to provide an update on insulin and ERK signaling in relation to memory, its decline in early AD, and provide an overview of clinical trials related to insulin for early AD intervention.",
keywords = "Alzheimer's disease, animal model, clinical trials, ERK, insulin resistance, learning and memory, metabolism, mitochondria, PPARγ",
author = "Lee, {Jung Hyun} and Jahrling, {Jordan B.} and Larry Denner and Kelly Dineley",
year = "2018",
month = "1",
day = "1",
doi = "10.3233/JAD-179923",
language = "English (US)",
volume = "64",
pages = "S427--S453",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "s1",

}

TY - JOUR

T1 - Targeting Insulin for Alzheimer's Disease

T2 - Mechanisms, Status and Potential Directions

AU - Lee, Jung Hyun

AU - Jahrling, Jordan B.

AU - Denner, Larry

AU - Dineley, Kelly

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Insulin resistance can occur when the body is unable to respond to insulin even in excess. In the brain, insulin manages glucose metabolism in regions such as the hippocampus and plays a key role in directly regulating ERK, a kinase required for the type of memory compromised in early Alzheimer's disease (AD). Human imaging studies show that brain glucose utilization declines with age and is notably impaired in subjects with early AD. Likewise, animal models of AD or insulin resistance, or both, demonstrate that dysfunctional insulin signaling and insulin resistance in the brain have reciprocity with neuroinflammation and aberrant accumulation of amyloid-β (Aβ), pathological hallmarks in AD. As such, the association between brain insulin activity and AD has led to clinical trials testing the efficacy of insulin and insulin-sensitizing drugs to intervene in AD. Based on recent inquiries to ClinicalTrials.gov, we evaluated thirty-three clinical studies related to AD and insulin. The search filtered for interventional clinical trials to test FDA-approved drugs or substances that impinge upon the insulin signaling pathway. Insulin, metformin, and thiazolidinediones were the three main interventions assessed. Overall, these strategies are expected to negate the effects of brain insulin resistance by targeting insulin signaling pathways involved in neuroinflammation, metabolic homeostasis, synaptic functional and structural integrity. The goal of this review is to provide an update on insulin and ERK signaling in relation to memory, its decline in early AD, and provide an overview of clinical trials related to insulin for early AD intervention.

AB - Insulin resistance can occur when the body is unable to respond to insulin even in excess. In the brain, insulin manages glucose metabolism in regions such as the hippocampus and plays a key role in directly regulating ERK, a kinase required for the type of memory compromised in early Alzheimer's disease (AD). Human imaging studies show that brain glucose utilization declines with age and is notably impaired in subjects with early AD. Likewise, animal models of AD or insulin resistance, or both, demonstrate that dysfunctional insulin signaling and insulin resistance in the brain have reciprocity with neuroinflammation and aberrant accumulation of amyloid-β (Aβ), pathological hallmarks in AD. As such, the association between brain insulin activity and AD has led to clinical trials testing the efficacy of insulin and insulin-sensitizing drugs to intervene in AD. Based on recent inquiries to ClinicalTrials.gov, we evaluated thirty-three clinical studies related to AD and insulin. The search filtered for interventional clinical trials to test FDA-approved drugs or substances that impinge upon the insulin signaling pathway. Insulin, metformin, and thiazolidinediones were the three main interventions assessed. Overall, these strategies are expected to negate the effects of brain insulin resistance by targeting insulin signaling pathways involved in neuroinflammation, metabolic homeostasis, synaptic functional and structural integrity. The goal of this review is to provide an update on insulin and ERK signaling in relation to memory, its decline in early AD, and provide an overview of clinical trials related to insulin for early AD intervention.

KW - Alzheimer's disease

KW - animal model

KW - clinical trials

KW - ERK

KW - insulin resistance

KW - learning and memory

KW - metabolism

KW - mitochondria

KW - PPARγ

UR - http://www.scopus.com/inward/record.url?scp=85048637083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048637083&partnerID=8YFLogxK

U2 - 10.3233/JAD-179923

DO - 10.3233/JAD-179923

M3 - Review article

C2 - 29710715

AN - SCOPUS:85048637083

VL - 64

SP - S427-S453

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - s1

ER -